← All trials
NCT04782076
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 5, 2021
- Primary completion
- May 17, 2021
- Completion date
- May 17, 2021
- First posted
- Mar 4, 2021
- Last posted
- Jul 16, 2021
- Enrollment
- 36
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Loxo OncologyLead sponsor
- Eli LillyStudy director
- Eli LillyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.